Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Payables (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 14 years of Payables data on record, last reported at $15.0 million in Q4 2024.

  • For Q4 2024, Payables fell 21.32% year-over-year to $15.0 million; the TTM value through Nov 2024 reached $15.0 million, down 21.32%, while the annual FY2024 figure was $16.3 million, 26.08% down from the prior year.
  • Payables reached $15.0 million in Q4 2024 per LFCR's latest filing, down from $18.0 million in the prior quarter.
  • Across five years, Payables topped out at $63.7 million in Q1 2020 and bottomed at $6.4 million in Q3 2020.
  • Average Payables over 5 years is $24.3 million, with a median of $16.3 million recorded in 2024.
  • Peak YoY movement for Payables: plummeted 86.24% in 2020, then surged 640.11% in 2021.
  • A 5-year view of Payables shows it stood at $8.0 million in 2020, then soared by 640.11% to $59.1 million in 2021, then tumbled by 52.67% to $28.0 million in 2022, then crashed by 31.99% to $19.0 million in 2023, then dropped by 21.32% to $15.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Payables were $15.0 million in Q4 2024, $18.0 million in Q3 2024, and $16.3 million in Q2 2024.